<DOC>
	<DOCNO>NCT02389920</DOCNO>
	<brief_summary>Describe purpose study : This study aim evaluate improvement Dasatinib-related adverse event evaluate treatment effect safety measure genetic response nilotinib nilotinib 400mg BID 12 month Philadelphia chromosome-positive chronic myeloid leukemia patient intolerant Dasatinib .</brief_summary>
	<brief_title>Multicenter , PhaseⅣ , Open Label Trial Nilotinib Adult Patients Diagnosed Philadelphia Chromosome Positive ( Ph+ ) Chronic Myeloid Leukemia CP/AP Intolerant Dasatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Men woman ≥ 19 year old 2 . Performance status ( ECOG ) 0 , 1 , 2 3 . Chronic phase accelerate phase chronic myeloid leukemia treat two week , switch nilotinib . 4 . Appropriate target organ function define ; Bilirubin &lt; 1.5 X ULN Liver function test , AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 X ULN Creatinine &lt; 1.5 X ULN Serum amylase lipase ≤ 1.5 X ULN Alkaline phosphatase ≤ 2.5 X ULN ( related tumor ) 5 . Women childbearing potential must negative pregnancy test ( urine serum ) within 7 day prior start study drug administration . 6 . Should laboratory result follow . Potassium ≥ LLN Magnesium ≥ LLN Phosphorus ≥ LLN 7 . Voluntary , sign date informed consent prior study procedure perform 1 . Subjects T315I mutation 2 . Mutation know associate low sensitivity nilotinib ( e.g. , Y253H , E255K , E255V , F359V ) , 3 . Cardiac function abnormality follow find . FEVI &lt; 45 % less low limit normal center ECG QT interval measure ECG Complete right bundle branch block Using ventricular pacemaker Congenital long QT syndrome family history long QT syndrome Past present clinically significant ventricular atrial tachycardia Clinically significant bradycardia rest ( &lt; 50 beats/min ) Regardless toxicity Dasatinib intake , QTc &gt; 480 msec ( use QTcF formula ) baseline ECG . If QTcF &gt; 480 msec electrolyte within normal range , necessary correct electrolytes reassess patient 's QTc . According result QTc , investigator make decision patient 's enrollment . Myocardial infarction within 12 month prior start study Other clinically significant heart disease ( e.g. , unstable angina , congestive heart failure uncontrolled hypertension ) 4 . Cytopathologically confirmed central nervous system lumbar puncture ( spinal tapping need suspect association central nervous system ) 5 . Severe uncontrolled disease ( e.g. , uncontrolled diabetes mellitus , active uncontrolled infection ) 6 . History significant congenital acquire , bleed disorder unrelated cancer 7 . 25 % bone marrow treat prior radiotherapy 8 . Not recover prior surgery major surgery within 4 week Day 1 study 9 . Treated investigational product within 30 day 10 . History noncompliance medical treatment unable voluntarily provide write sign date informed consent 11 . Other primary cancer currently clinically significant require active treatment 12 . Currently treat strong CYP3A4 inhibitor ( e.g. , erythromycin , ketoconazole , itraconazol , voriconazol , clarithromycin , telithromycin , ritonavir , mibefradil ) , treatment stop switch drug start study drug administration ( For complete list , refer link : http : //medicine.iupui.edu/flockhart/table.htm . ) 13 . Gastrointestinal dysfunction gastrointestinal disease may significantly change absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass ) 14 . History acute pancreatitis within past 1 year history chronic pancreatitis 15 . Acute chronic uncontrolled liver , pancreas severe renal disease unrelated disease 16 . Currently treat drug may prolong QT interval , treatment stop switch drug start study drug administration ( For complete list product prolong QT interval , refer http : //www.torsades.org/medicalpros/druglists/printabledruglist.cfm ) 17 . Pregnant woman , breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>